Companies /Healthcare

Solventum Corp.

NYSE: SOLV Medical Instruments & Supplies
$85.93
▼ $1.37 (−1.56%) today
Markets open · 3:34pm ET

24/7 Wall St. View

SOLV at a Glance

Valuation
Market cap
$14.9B
P/E ratio
10.7
Profitability
Revenue (TTM)
$8.3B
Profit margin
17.3%
EPS (TTM)
$8.17
Price
52-week range
$62 – $94
24/7 target
$108.92
Street target
$94.31
Earnings
Next report
Nov 5, 2026

Headquartered in Eagan, MN Fiscal year ends December NYSE: SOLV solventum.com

About Solventum

Solventum Corporation is a healthcare technology company spun off from 3M in 2024 that operates at the intersection of health, material, and data science. The company is organized into three reportable segments: MedSurg (which encompasses Advanced Wound Care products such as negative pressure wound therapy and advanced dressings, and Infection Prevention and Surgical Solutions including IV site management, sterilization assurance, surgical supplies, and medical electrodes), Dental Solutions (dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents), and Health Information Systems (software solutions for healthcare revenue cycle management including computer-assisted physician documentation, coding automation, speech recognition, and data visualization). The company sold its Purification and Filtration business in September 2025 and has announced its intent to separate the Health Information Systems segment to sharpen its focus as a dedicated MedTech company. Solventum acquired Acera Surgical in December 2025 to bolster its wound care portfolio. The company serves healthcare professionals and systems globally with products designed to improve clinical outcomes and operational efficiency. Updated

SOLV Coverage

Frequently Asked Questions

What does Solventum do?

Solventum Corporation is a healthcare technology company spun off from 3M in 2024 that operates at the intersection of health, material, and data science.

What is the SOLV stock price target?

24/7 Wall St.'s 12-month price target for SOLV is $108.92, rated Buy. The Wall Street consensus target is $94.31. SOLV price prediction →